摘要
目的:探讨环丝氨酸联合莫西沙星治疗耐多药肺结核(MDR-TB)的疗效及对免疫功能和生活质量的影响。方法:选取2016年7月到2018年10月期间我院收治的MDR-TB患者86例作为研究对象,根据奇偶排序法将患者分为对照组(n=43,基础治疗联合莫西沙星治疗)和研究组(n=43,对照组基础上联合环丝氨酸治疗),均治疗20个月。对比两组疗效、痰结核菌转阴率、病灶吸收率、空洞缩小率情况、免疫功能、生活质量及不良反应。结果:研究组治疗20个月后的总有效率高于对照组(P<0.05)。研究组治疗12个月后、治疗20个月后痰结核菌转阴率、病灶吸收率、空洞缩小率均高于对照组(P<0.05)。两组治疗20个月后心理功能、躯体功能、社会功能、物质生活评分均升高,且研究组高于对照组(P<0.05)。两组治疗20个月后CD8+较治疗前降低,且研究组低于对照组(P<0.05),CD3+、CD4+/CD8+、CD4+较治疗前升高,且研究组高于对照组(P<0.05)。对比两组不良反应发生率无差异(P>0.05)。结论:环丝氨酸联合莫西沙星治疗MDR-TB,能够有效的促进患者机体免疫功能和生活质量的改善,并能够有效的促进临床转归,且用药安全性较高。
Objective:To investigate the curative effect of cycloserine combined with moxifloxacin in the treatment of multi drug resistant pulmonary tuberculosis(MDR-TB)and its influence on immune function and quality of life.Methods:86 cases of MDR-TB patients who were admitted in our hospital from July 2016 to October 2018 were selected as the research objects,they were divided into the control group(n=43,basic treatment combined with moxifloxacin treatment)and the study group(n=43,combined with cycloserine treatment on the basis of the control group)according to the parity ranking method,all patients were treated for 20 months.The curative effect,sputum tuberculosis negative conversion rate,focus absorption rate,cavity shrinkage rate,immune function,quality of life and adverse reactions were compared between the two groups.Results:The total effective rate of the study group after 20 months of treatment was higher than that of the control group(P<0.05).The sputum tuberculosis negative conversion rate,focus absorption rate,cavity shrinkage rate of the study group were higher than those of the control group after 12 months of treatment,20 months of treatment(P<0.05).The scores of psychological function,physical function,social function,material life in the two groups were increased,and the scores in the study group were higher than those in the control group after 20 months of treatment,and the study group was higher than the control group(P<0.05).CD8+in the two groups were lower than those of before treatment after 20 months of treatment,and the study group was lower than the control group(P<0.05),and CD3+,CD4+/CD8+,CD4+were higher than those of before treatment,and the study group were higher than the control group(P<0.05).There was no difference in adverse reactions between the two groups(P>0.05).Conclusion:Cycloserine combined with moxifloxacin in the treatment of MDR-TB,can effectively promote the improvement of immune function and personal quality of life of patients,and can effectively promote the clinical outcome,and the drug safety is high.
作者
王丹
张耀之
余梅
何燕
刘祥敏
薛秒
WANG Dan;ZHANG Yao-zhi;YU Mei;HE Yan;LIU Xiang-min;XUE Miao(Department of Respiratory and Critical Care Medicine,West China Hospital of Sichuan University,Chengdu,Sichuan,610041,China)
出处
《现代生物医学进展》
CAS
2021年第16期3044-3048,共5页
Progress in Modern Biomedicine
基金
四川省卫生和计划生育委员会科研项目(17PJ043)。
关键词
莫西沙星
环丝氨酸
耐多药肺结核
疗效
免疫功能
生活质量
Moxifloxacin
Cycloserine
Multi drug resistant pulmonary tuberculosis
Curative effect
Immune function
Quality of life
